Data were analysed using SPPS version 21 (IBM, USA) and Stata 12.1 (StataCorp, USA). Continuous variables were summarised using means and standard deviations (SDs).
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A lack of good-quality data makes it difficult to understand the burden of oncological disease in South Africa (SA) and to establish priorities or benchmark outcomes. Gastric cancer (GC) is the fifth most common visceral malignancy in the world, and the thirdhighest cause of cancer-related death. [1] According to the SA National Cancer Registry (reported on the Cancer Association of South Africa website), there were over 1 000 cases of GC in SA in 2010.
[2] However, there are major deficiencies in this registry, and cancer data are poorly reported nationwide. [1, 2] In addition, the diverse nature of the SA population means that the burden of oncological disease varies between centres and population groups. The mixed-race population of the Western Cape Province is known to have a high incidence of the disease. The situation in KwaZulu-Natal (KZN) Province has not been described previously. In the light of these challenges the best data available are regional hospital-based data, and despite the obvious limitations of such data, researchers have to use this information to identify potential trends and areas that deserve more thorough investigation.
Objective
This retrospective audit of a prospectively maintained central hospital medical record system is intended to provide a description of the spectrum of GC seen in KZN and to benchmark the management of the disease against local and international guidelines. [3] It was hoped that data on risk factors for the development of GC in our environment could be analysed.
Methods

Study design and inclusion and exclusion criteria
A retrospective review of a prospectively maintained electronic patient record system was undertaken to identify all patients with GC who were diagnosed or treated at the quaternary referral centre Inkosi Albert Luthuli Central Hospital (IALCH) in Durban, SA, between January 2009 and April 2014. All patients seen at IALCH with histologically proven GC were included. All data were retrieved from patients' digital files. 
Benchmarking
We attempted to stage each lesion according to the TNM staging system for GC based on the available histological data. After each patient had been staged, their treatment regimen was reviewed to see whether it complied with current international recommendations as presented on the Cancer Association of South Africa website.
[2]
Results
Patient demographics
A total of 131 patients with GC were identified for the period 2009 -2014. The patient demographics are set out in Table 1 . Of the 131 patients, 48.1% (n=63) were Indian and 45.0% (n=59) black African. The proportions of male and female patients were 55.0% (n=72) and 45.0% (n=59), respectively. The mean age for all patients was 60 years (SD 13.3).
Family history
The results for a family history of cancer, alcohol use and smoking are set out in Table 1 . Of the patients, 13.0% (n=17) had a firstdegree family history of cancer. Most of these patients were Indian (n=11), and four patients had a family history of GC. Use of alcohol was reported by 30.5% of the patients (n=40), and smoking by 35.1% (n=46). Table 1 
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Stage of GC at first presentation
Location of the tumour
The locations of the tumours in the stomach on gastroscopy are set out in Table 2 . The most common locations of GC were the body and distal parts of the stomach (antrum and pylorus) (50/128, 39.1% and 47/128, 36.7%, respectively).
Body mass index (BMI) and relation between BMI and location of the tumour
The overall mean BMI was 22.2 kg/m 2 (SD 5.2). The relationship between BMI and locations of the tumours is set out in Table 2 . This was found not to be significant (p=0.175).
Histological findings
The intestinal histological variants and grades of the tumours are set out in Table 2 . All were adenocarcinomas. No histological changes were reported for most (84.0%) of the patients (n=110), although rates of intestinal metaplasia, atrophic gastritis and dysplasia were reported as 6.8% (n=9), 7.6% (n=10) and 1.5% (n=2), respectively. Nearly half of the patients (n=63, 48.1%) had intestinal-type adenocarcinomas, while diffuse-type adenocarcinomas were present in 16.8% (n=22).
Blood results
The median serum creatinine level was 71.0 mmol/L (IQR 57.0 -91.5), the mean albumin level 35.2 mmol/L (SD 9.4), and the median haemoglobin level 10.8 g/dL (IQR 8.7 -12.0) ( Table 3) .
Surgery and chemoradiotherapy
The types of operations and chemoradiotherapy are set out in Table 4 . Type of operation and chemoradiotherapy were significantly associated (p<0.001). Most of the patients presented with advanced disease that was not resectable, and 72.5% (n=95) did not undergo surgery with curative intent owing to advanced disease. Only 1 patient (0.1%) had neoadjuvant chemotherapy, 21 (16.0%) had adjuvant chemotherapy, and 17 (13%) had radiotherapy.
Discussion
Our data show some interesting local variations. There appears to be a relatively high burden of GC in the Indian population, as evidenced by the observation that Indian patients made up 48.1% of the GC patients in our series yet only comprise 7.4% of the population of KZN. [4] This observation may simply reflect referral bias, and ongoing audit is required to see whether this apparent racial difference is a real phenomenon. There was a slight male preponderance, with 55.0% males and 45.0% females. There were no significant age differences with regard to gender and ethnicity. World Health Organization statistics show that GC is more common in males than females, and relatively common in Asian countries such Japan and Korea, while it is rare in southern African countries. [5, 6] Comparing our findings with international data revealed some areas of similarity and some differences. Our findings concur with those from the literature that the most common sites of GC were the body of the stomach and the distal stomach, [7] but differ from those of Kubo and Corley, [8] who found that there was a significant relationship between BMI and tumour location. In a systematic review of 14 studies involving 2 488 oesophageal and 2 509 gastric adenocarcinomas, they found a positive association between a high BMI and risk of oesophageal and possibly proximal gastric adenocarcinomas. The mean BMI in our study was 22 kg/m 2 . Yang et al., [9] in a meta-analysis of cohort studies with 9 492 GC patients, found that a BMI of >25 kg/m 2 was associated with a high risk of GC. Our findings that 48.1% of the patients had the intestinal type and 16.8% the diffuse type of GC do not concur with those of Lauren, [10] who found prevalences of 70% and 30%, respectively, for the diffuse and intestinal types of GC. Our median haemoglobin concentration of 10.8 g/dL is in agreement with Wanebo et al. ' s [11] finding that occult gastrointestinal bleeding with or without iron deficiency anaemia is common in patients with GC.
It is generally understood that human gastric carcinogenesis is a multistep and multifactorial process with sequential histopathological stages. These stages start with Helicobacter pylori infection, then develop into chronic active non-atrophic gastritis, multifocal atrophic gastritis, intestinal metaplasia (complete then incomplete), dysplasia, and finally invasive carcinoma. [12] The International Agency for Research on Cancer [13] recognises infection by H. pylori as a primary cause of gastric adenocarcinoma. However, most patients in our series did not display such histological changes, and H. pylori was associated with GC in only seven patients in this series. This app- 
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arent discrepancy between a high incidence of H. pylori infection and a relatively low incidence of GC has been termed the ' African enigma' . [14] However, more recent reports have tended to downplay the African enigma, and most authors now do not consider that it adequately accounts for the pathogenesis of GC. [14] Current opinion is that the contribution of H. pylori to development of GC in Africa is complex and almost certainly modulated by an interplay of diverse factors such as genetic susceptibility, the environment, dietary intake, and other pathogenic organisms such as Epstein-Barr virus (EBV). [14] Thirty-one percent of the patients in our study used alcohol. The relationship between alcohol consumption and GC is poorly understood, and some authors suggest that it may actually protect against the development of GC. [15] The situation is slightly clearer with regard to smoking, and a recent meta-analysis has shown that smoking increases the risk of developing GC 1.53-fold. [16] Thirtyfive percent of the patients in our series were smokers. Thirteen percent had a first-degree family history of cancer, four having relatives with GC and another four relatives with breast cancer. This familial relationship has been demonstrated in other large reviews of GC.
Almost all studies of GC in the developing world are bedevilled by the issue of referral bias and the lack of robust high-quality cancer registries. Patients with GC may not present to healthcare providers, and those who do may not be captured in the existing data registries. The need for accurate, robust and sustainable cancer registries in the developing world is well recognised, and most established data sources have major limitations. Almost all those who have written on this topic concur that the epidemiology and pathogenesis of GC require ongoing investigation. Any future studies must examine the synergistic role of H. pylori, EBV and dietary antioxidants in the pathogenesis of GC in Africa. [14] Just over 70% (n=95) of the patients in our study had no operation or staging intervention and/or a gastric bypass procedure (Table 4) , because of the advanced stage of the disease. The majority of patients with GC in our environment present with advanced disease. This is a well-described problem with almost all malignancies in SA. Better cancer awareness, screening programmes and improved access to healthcare are needed to try to improve this situation. The lack of good-quality staging is a concern, as treatment regimens are based on TNM staging. [3] Only 1 patient had neoadjuvant chemotherapy, 21 had adjuvant chemotherapy and 17 had radiotherapy. There is much debate about optimal treatment regimens, but most authors now agree that surgery needs to be combined with other modalities of treatment. Macdonald et al. [17] found that postoperative chemoradiotherapy should be considered for all patients at high risk of recurrence of adenocarcinoma of the stomach who have undergone curative resection. Forty patients in our study had palliative chemotherapy. In a meta-analysis of three trials comparing chemotherapy and the best supportive care, Wagner et al. [18] found that chemotherapy significantly improved survival in comparison with best supportive care. In addition, a perioperative regimen decreased tumour size and stage and significantly improved progression-free and overall survival. [19] It is clear that we lack well-structured treatment regimens for GC in our environment. We need to improve our ability to stage the malignancy and to develop multidisciplinary team (MDT)-based algorithms to ensure that patients with GC receive the most appropriate treatment available.
Study limitations
Owing to the retrospective nature of the study, incomplete data and poor follow-up may limit the information available for analysis. In addition, the study was limited to one centre that may not represent the general population. It was also not possible to obtain information on outcomes (survival rate) because of the referral system and difficulty in obtaining data from primary and secondary hospitals.
Conclusions
GC appears to have a higher incidence in the Indian than in the black African population of KZN. This is in keeping with the current literature on GC in sub-Saharan Africa. Most of the patients with GC in our environment present with advanced disease and do not undergo curative surgery. Our ability to stage these tumours accurately is limited, and this needs to be improved. Appropriate therapy depends on good TNM staging. It is essential that MDTbased algorithms are developed to ensure that therapy is appropriate.
